# A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct04895709/  
OnCo record `nct04895709` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Nivolumab, Docetaxel, PM8002 in cervical cancer and colorectal cancer, run by Bristol-Myers Squibb, now recruiting.

## Summary

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04895709 by Bristol-Myers Squibb, with 1109 participants planned, started 2021-05-27 and due to reach its primary completion in 2031-08-31. Interventions recorded: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig. Conditions listed: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04895709
- Phase: 1/2
- Setting: A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Sponsor: Bristol-Myers Squibb
- Enrolled: 1109

## Sources

- ClinicalTrials.gov NCT04895709: https://clinicaltrials.gov/study/NCT04895709

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct04895709.json